Davis Polk advised the representatives of the several underwriters in the offering.Century Therapeutics, Inc. executed the $242.7 million initial public offering of 12,132,500 shares of Class…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
